A Phase II Study of AT-101 to Overcome Bcl-2 Mediated Resistance to Androgen Deprivation Therapy in Patients with Newly Diagnosed Castration Sensitive Metastatic Prostate Cancer

BACKGROUND: We conducted a phase II study in men with castration sensitive metastatic prostate cancer to test the hypothesis that AT-101, a small molecule Bcl-2 inhibitor, has clinical activity in patients initiating androgen deprivation therapy (ADT) for metastatic prostate cancer. METHODS: Patient...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Genitourin Cancer
Auteurs principaux: Stein, Mark N., Hussain, Maha, Stadler, Walter M., Liu, Glenn, Tereshchenko, Irina V., Goodin, Susan, Jeyamohan, Chandrika, Kaufman, Howard L., Mehnert, Janice, DiPaola, Robert S.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4698193/
https://ncbi.nlm.nih.gov/pubmed/26476589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2015.09.010
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires